Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin, linagliptin, and gliclazide effects on renal physiology in metformin-treated type 2 diabetes
2017-001547-12Phase 4Completed
- Sponsor
- VU University Medical Center
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin, linagliptin and gliclazide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by VU University Medical Center. Primary endpoints: Renal hemodynamics and Renal tubular function. Started Nov 2017; status: completed.
02
Drugs
empagliflozinlinagliptingliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001547-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001547-12.